FibroGen Inc - Asset Resilience Ratio
FibroGen Inc (FGEN) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of FibroGen Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how FibroGen Inc's Asset Resilience Ratio has changed over time. See FGEN net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down FibroGen Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see FGEN stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: FibroGen Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
FibroGen Inc Industry Peers by Asset Resilience Ratio
Compare FibroGen Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for FibroGen Inc (2012–2024)
The table below shows the annual Asset Resilience Ratio data for FibroGen Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $214.53 Million | -- |
| 2023-12-31 | 28.78% | $121.90 Million | $423.53 Million | -14.87pp |
| 2022-12-31 | 43.65% | $266.31 Million | $610.09 Million | +13.42pp |
| 2021-12-31 | 30.24% | $233.97 Million | $773.82 Million | +29.25pp |
| 2020-12-31 | 0.98% | $8.14 Million | $826.84 Million | -46.54pp |
| 2019-12-31 | 47.53% | $407.49 Million | $857.40 Million | -12.90pp |
| 2018-12-31 | 60.43% | $532.14 Million | $880.60 Million | +53.52pp |
| 2017-12-31 | 6.91% | $62.06 Million | $898.65 Million | -10.00pp |
| 2016-12-31 | 16.91% | $79.40 Million | $469.55 Million | +10.99pp |
| 2015-12-31 | 5.92% | $27.85 Million | $470.57 Million | +2.95pp |
| 2014-12-31 | 2.97% | $14.36 Million | $483.53 Million | -12.68pp |
| 2013-12-31 | 15.65% | $46.48 Million | $296.95 Million | +15.27pp |
| 2012-12-31 | 0.38% | $1.02 Million | $265.59 Million | -- |
About FibroGen Inc
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and o… Read more